ESSA Pharma Inc. (EPIX)
Oct 9, 2025 - EPIX was delisted (reason: acquired by XenoTherapeutics)
0.1951
-0.0061 (-3.03%)
Inactive · Last trade price on Oct 8, 2025
ESSA Pharma Stock Forecast
EPIX's stock price has decreased by -96.63% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for ESSA Pharma stock has a target of 2.00, which predicts a 925.12% increase from the current stock price of 0.2.
Price Target: $2.00 (+925.12%)
Analyst Consensus: Hold
* Price targets were last updated on Nov 4, 2024.
Analyst Ratings
The average analyst rating for ESSA Pharma stock from 3 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $15 → $2 | Buy → Hold | Downgrades | $15 → $2 | +925.12% | Nov 4, 2024 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 4, 2024 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 1, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $17 | Buy | Maintains | $17 | +8,613.48% | May 16, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $17 | Buy | Reiterates | $17 | +8,613.48% | Dec 13, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
22.72M
EPS This Year
-0.72
from -0.64
EPS Next Year
-0.18
from -0.72
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | 23.4M | |
| Avg | n/a | 22.7M | |
| Low | n/a | 21.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.75 | -0.19 | |
| Avg | -0.72 | -0.18 | |
| Low | -0.70 | -0.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.